Document Detail

Case reports: practical experience with efalizumab in hand and foot psoriasis.
MedLine Citation:
PMID:  18189064     Owner:  NLM     Status:  MEDLINE    
Psoriasis of the hands and feet is highly debilitating and difficult to treat. It may be of a plaque-or pustular-type, or a combination of the two. Efalizumab (Raptiva, Genentech Inc), a humanized monoclonal antibody that inhibits critical T cell-mediated processes, is approved by the FDA for the treatment of adult patients with chronic moderate to severe plaque psoriasis. We present the cases of 7 patients who suffered from extensive hand and foot psoriasis recalcitrant to treatment. Each patient was treated with 1 mg/kg/wk of efalizumab and responded rapidly to treatment with favorable results appearing within 1 to 4 months. Patients were able to resume previous work responsibilities and no longer suffered from difficulties with ambulation. Efalizumab was effective for the rapid treatment of these 7 patients with psoriasis of the hands and feet.
David J Cohen; Lubomira Scherschun
Related Documents :
22278794 - Stereotactic brainstem biopsy in a patient with coagulopathy of unclear etiology: case ...
2568064 - Treatment of psoriasis with a new uvb-lamp.
22913794 - Continuous venovenous hemodialysis with regional citrate anticoagulation in patients wi...
8407074 - Update on nutrition and psoriasis.
20941934 - Laboratory examination of seronegative and seropositive rheumatoid arthritis.
24294924 - Airway oxidative stress in chronic cough.
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Journal of drugs in dermatology : JDD     Volume:  6     ISSN:  1545-9616     ISO Abbreviation:  J Drugs Dermatol     Publication Date:  2007 Dec 
Date Detail:
Created Date:  2008-01-14     Completed Date:  2008-02-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101160020     Medline TA:  J Drugs Dermatol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1224-30     Citation Subset:  IM    
Mercer University, Macon, GA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / adverse effects,  therapeutic use*
Foot Dermatoses / drug therapy*,  pathology
Hand Dermatoses / drug therapy*,  pathology
Immunologic Factors / adverse effects,  therapeutic use*
Middle Aged
Psoriasis / drug therapy*,  pathology
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Immunologic Factors; 0/efalizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Case reports: type I hypersensitivity to lidocaine.
Next Document:  Tissue tightening: a hot topic utilizing deep dermal heating.